Sung Ji Nam
Stock Analyst at Scotiabank
(2.01)
# 2,995
Out of 4,911 analysts
82
Total ratings
41.18%
Success rate
-7.92%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TECH Bio-Techne | Maintains: Sector Outperform | $90 → $75 | $58.47 | +28.27% | 3 | Jul 11, 2025 | |
| DHR Danaher | Upgrades: Sector Outperform | $275 | $202.81 | +35.59% | 2 | Jul 11, 2025 | |
| TMO Thermo Fisher Scientific | Upgrades: Sector Outperform | $590 | $475.03 | +24.20% | 15 | Jul 11, 2025 | |
| ILMN Illumina | Downgrades: Sector Perform | $125 | $107.64 | +16.13% | 10 | Jul 11, 2025 | |
| CSTL Castle Biosciences | Maintains: Sector Outperform | $44 → $40 | $16.43 | +143.46% | 6 | May 21, 2025 | |
| BDSX Biodesix | Maintains: Sector Outperform | $3 → $2 | $0.42 | +378.81% | 2 | May 21, 2025 | |
| MYGN Myriad Genetics | Downgrades: Sector Perform | $20 → $6 | $4.65 | +29.03% | 4 | May 21, 2025 | |
| GH Guardant Health | Maintains: Sector Outperform | $52 → $57 | $45.49 | +25.30% | 5 | May 5, 2025 | |
| BNGO Bionano Genomics | Maintains: Sector Perform | $1 → $4 | $3.46 | +15.61% | 6 | Apr 2, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Sector Outperform | $6 → $2 | $1.54 | +29.87% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $70 → $73 | $48.77 | +49.68% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $10 → $12 | $10.66 | +12.57% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $430 → $450 | $298.47 | +50.77% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $54 → $62 | $35.08 | +76.74% | 5 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $40 → $44 | $23.59 | +86.52% | 4 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $12.84 | +172.59% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $5.17 | +16.05% | 2 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $18.41 | - | 3 | Nov 24, 2020 |
Bio-Techne
Jul 11, 2025
Maintains: Sector Outperform
Price Target: $90 → $75
Current: $58.47
Upside: +28.27%
Danaher
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $275
Current: $202.81
Upside: +35.59%
Thermo Fisher Scientific
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $590
Current: $475.03
Upside: +24.20%
Illumina
Jul 11, 2025
Downgrades: Sector Perform
Price Target: $125
Current: $107.64
Upside: +16.13%
Castle Biosciences
May 21, 2025
Maintains: Sector Outperform
Price Target: $44 → $40
Current: $16.43
Upside: +143.46%
Biodesix
May 21, 2025
Maintains: Sector Outperform
Price Target: $3 → $2
Current: $0.42
Upside: +378.81%
Myriad Genetics
May 21, 2025
Downgrades: Sector Perform
Price Target: $20 → $6
Current: $4.65
Upside: +29.03%
Guardant Health
May 5, 2025
Maintains: Sector Outperform
Price Target: $52 → $57
Current: $45.49
Upside: +25.30%
Bionano Genomics
Apr 2, 2025
Maintains: Sector Perform
Price Target: $1 → $4
Current: $3.46
Upside: +15.61%
Pacific Biosciences of California
Mar 25, 2025
Maintains: Sector Outperform
Price Target: $6 → $2
Current: $1.54
Upside: +29.87%
Feb 24, 2025
Maintains: Sector Outperform
Price Target: $70 → $73
Current: $48.77
Upside: +49.68%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $10 → $12
Current: $10.66
Upside: +12.57%
Feb 13, 2025
Upgrades: Sector Outperform
Price Target: $430 → $450
Current: $298.47
Upside: +50.77%
Feb 4, 2025
Maintains: Sector Outperform
Price Target: $54 → $62
Current: $35.08
Upside: +76.74%
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $23.59
Upside: +86.52%
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $12.84
Upside: +172.59%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $5.17
Upside: +16.05%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $18.41
Upside: -